LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Technical Report > Policy Brief

DR-TB drugs under the microscope 2022

MSF Access Campaign
Download
Download
Abstract
TB was the leading cause of death from a single infectious agent until the COVID pandemic. The number of people newly diagnosed with TB in 2020 fell by 18% from the previous year due to disruptions to health systems and services caused by the pandemic, with only a partial recovery in 2021. As a result, in 2021, only one in three people with drug-resistant TB (DR-TB) received treatment for the disease.

However, since the onset of the pandemic, more effective and patient-friendly treatments and regimens for adults and children have become available to the TB community. Now more than ever there is a need to accelerate treatment and save more lives.

This Issue Brief – the eighth in this series – by Médecins Sans Frontières (MSF)’s Access Campaign, examines the current landscape and trends of DR-TB drug pricing and patents, and highlights challenges and opportunities to accelerate people’s access to lifesaving regimens that are shorter, all-oral and make use of the most effective medicines.
Subject Area
antibiotic resistancetuberculosisantimicrobial resistanceaccess to health care
Collections
TB-PRACTECAL Trial—Evidence for a shorter, safer, more effective treatment for drug-resistant tuberculosisExpanding access to lifesaving new TB toolsThe endTB project
DOI
10.57740/zxbm-0414
Published Date
08-Nov-2022
Languages
English